Franck Le Deu’s Post

#PBPK and #QSP for #biologics. Done with #PKSim and #MoBi of the #opensource software #OSPSuite Join the #OSPCommunityConference to learn more!

Success Cases of the TRYOUT PoC Program 🔎👀 ① Incheon Port Authority [Video-based AI Parking Analysis System] Korea’s first introduction of an image-based AI parking analysis system to the seaport ② Samsung Biologics [Liquid Handling Robot for Protein Purification] The PoC product purchased by Samsung Biologics, 47 purchase intentions worth 3.3 billion won received and investment worth 4 billion won attracted ③ Inha University Hospital Efficacy Center [Closed System Transfer Device(CSTD)] Designated as an innovative product by the Public Procurement Service, FDA approved and investment worth 1.9 billion won attracted

👨🔬 👩🔬 Large and small molecule-based drug discovery will be in the spotlight at a pair of symposia in Europe this week! ⏩ With the theme 'Unlocking High-throughput Biology in Drug Discovery' the meetings in Oxford and Utrecht are organised by Carterra and industry partners Large molecules Amongst the exciting agenda of presentations from academic and industry researchers, look out for two new application notes developed by scientists from Bio-Techne's protein sciences team leveraging the Carterra LSA's capabilities for high-throughput biophysical characterisation: 🛠 Comparing recombinantly engineered biosimilar antibodies with originator therapeutic antibodies 🏎 Acceleratating antibody pair screening for immunoassay applications Small molecules We're also excited to have been collaborating with the Carterra applications team, who will highlight capabilities for high-throughput SPR based small-molecule drug discovery applications, using tools developed by Bio-Techne chemists: 🎯 Targeted protein degradation 🛑 Kinase inhibitors #drugdiscovery

Unravel the secret of XDCs with Leo Liu, Ph.D., as he presents an enlightening webinar on the increasing role of light scattering in XDC development. Get to know how this tech can improve quality control parameters, add vigor to hands-on lab efficiency, and open new realms in the study of complex hybrid biologics. https://lnkd.in/ghVdvupg

Selecting an #ADC linker architecture requires understanding how the relationship between a linker’s structure, drug payload, and drug-to-antibody ratio (DAR) alters efficacy, stability, hydrophilicity, physicochemical properties, and off-target toxicity. This #webinar is a good platform to learn how to select or design the most optimal linker for your ADC. Be sure to register to accelerate your #biotherapeutic development journey!

Register for our webinar next month to learn more about how our portfolio of linkers is expanding the potential and effectiveness of antibody drug conjugates!

RNA-targeted drugs are a promising new therapeutic approach, but discovery and development remains a challenge for biotech and pharma. So, what’s holding the field back? Current approaches to analysing interactions between drug candidates and target RNAs have several limitations. Our unique scalable Magnetic Force Spectroscopy platform overcomes them. Find out how by swiping through our slides below 👇

Join Vector Laboratories, Inc. for an exciting webinar regarding influencing ADC performance through linker design. Register below and set a reminder for May 21st at 2pm EDT! Don't miss out! #lifescience #ADC #biotechnology

Certest Pharma, a Spanish biotech company I encountered at the 2024 USBIO, has developed proprietary Lipid Nanoparticle (LNP) technology, with a special focus on ionizable lipids. In 2023, they filed a patent (WO2024110381A1) that claims a series of ionizable lipid molecules based on a primary formula. The LNPs containing these specific ionizable lipids demonstrate varying RNA encapsulation efficiencies and different physical properties. Certest Pharma also evaluated the transfection efficiency of these novel lipids in various formulations, comparing them with existing formulations used by BioNTech and Moderna. Many companies are developing their own ionizable lipids and filing patents for them. While some may achieve high delivery efficiency, other factors such as toxicity and overall competitiveness are equally important in determining their practical application. https://lnkd.in/gfXj3UtF

💊 [Bioproduction – French CDMO landscape] France is the European leader in terms of the number of production sites. 31 French biomanufacturing sites belong to 19 CDMOs! The French CDMOs are divided according to the type of batches produced: - 6 sites for clinical and commercial batches - 7 sites for preclinical and clinical batches - 18 sites for preclinical, clinical and commercial batches   🔔💡 Not to be missed! To highlight the French industry, France BioLead is launching National Day of Biomanufacturing and Biomedicine on 5 July 2024. 📅 See you in Toulouse for an unmissable event organized by Just - Evotec Biologics, GTP Bioways, Flash BioSolutions and TWB, with the support of Bio'Occ : projet Biothérapie et Bioproduction en Occitanie, Eurobiomed and Leem. 🔬 #Biotechnology #Biomedicines #Bioproduction #Biomanufacturing #JNBB2024